How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Hereditary Angioedema Therapeutics Market
- By Therapeutic Class: C1 Esterase Inhibitors, Kallikrein Inhibitors, Bradykinin B2 Receptor Antagonists, Plasma-Derived C1-INH Concentrates, Recombinant C1-INH
- By Treatment Indication: Acute Attack Treatment, Prophylactic Treatment, Short-Term Prophylaxis
- By Route of Administration: Intravenous, Subcutaneous, Oral
- By Patient Population: Pediatric Patients, Adult Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - C1 Esterase Inhibitors leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.159 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.167 →
Full report · locked preview
Everything inside the Hereditary Angioedema Therapeutics Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Treatment Indication 3
Route of Administration 3
Patient Population 2
Companies profiled
Takeda Pharmaceutical Company Limited
BioCryst Pharmaceuticals Inc.
Pharming Group N.V.
CSL Behring (a CSL Limited company)
KalVista Pharmaceuticals Inc.
Sobi (Swedish Orphan Biovitrum AB)
Horizon Therapeutics plc
Shire (now part of Takeda)
Octapharma AG
Ionis Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Sanofi
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BioCryst Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pharming Group N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →CSL Behring (a CSL Limited company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →KalVista Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sobi (Swedish Orphan Biovitrum AB)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Horizon Therapeutics plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Shire (now part of Takeda)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Octapharma AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ionis Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Regeneron Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,451M by 2033 · 4.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- C1 Esterase Inhibitors48.5
- Kallikrein Inhibitors9.3
- Bradykinin B2 Receptor Antagonists15.1
- Plasma-Derived C1-INH Concentrates16.7
- Recombinant C1-INH10.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,252M → $1,799M · 4.6%
Europe$872.6M → $1,203M · 4.1%
Asia Pacific$796.7M → $1,237M · 5.6%
Latin America$493.2M → $650.8M · 3.5%
Middle East and Africa$379.4M → $536.8M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.592026
4.592027
4.612028
4.622029
4.622030
4.642031
4.662032
4.672033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Takeda Pharmaceutical Company Limited12.7
- BioCryst Pharmaceuticals Inc.17.1
- Pharming Group N.V.12.5
- CSL Behring (a CSL Limited company)5.3
- KalVista Pharmaceuticals Inc.18.1
- Sobi (Swedish Orphan Biovitrum AB)6.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class13.4%
Treatment Indication21.6%
Route of Administration29.8%
Patient Population35.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe22.2
- Asia Pacific22.8
- Latin America12.0
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 84 | 96 | 92 | 77 | 78 | 86 | 86 |
| BioCryst Pharmaceuticals Inc. | 85 | 75 | 79 | 79 | 76 | 77 | 79 |
| Pharming Group N.V. | 82 | 80 | 67 | 67 | 79 | 69 | 74 |
| CSL Behring (a CSL Limited company) | 75 | 61 | 78 | 72 | 65 | 81 | 72 |
| KalVista Pharmaceuticals Inc. | 59 | 68 | 63 | 53 | 72 | 61 | 63 |
| Sobi (Swedish Orphan Biovitrum AB) | 63 | 55 | 51 | 69 | 66 | 52 | 59 |
| Horizon Therapeutics plc | 43 | 64 | 56 | 47 | 65 | 40 | 53 |
| Shire (now part of Takeda) | 51 | 53 | 38 | 38 | 47 | 43 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Takeda Pharmaceutical Company Limited
- BioCryst Pharmaceuticals Inc.
- Pharming Group N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| BioCryst Pharmaceuticals Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Pharming Group N.V. | ✓ | ◐ | ◐ | − | ✓ | ◐ |
| CSL Behring (a CSL Limited company) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| KalVista Pharmaceuticals Inc. | − | ✓ | ◐ | − | ✓ | − |
| Sobi (Swedish Orphan Biovitrum AB) | ◐ | − | ◐ | ◐ | ◐ | − |
| Horizon Therapeutics plc | − | ◐ | − | ◐ | ◐ | − |
| Shire (now part of Takeda) | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Takeda Pharmaceutical Company Limited86
2BioCryst Pharmaceuticals Inc.79
3Pharming Group N.V.74
4CSL Behring (a CSL Limited company)72
5KalVista Pharmaceuticals Inc.63
6Sobi (Swedish Orphan Biovitrum AB)59
7Horizon Therapeutics plc53
8Shire (now part of Takeda)45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Takeda Pharmaceutical Company LimitedBioCryst Pharmaceuticals Inc.
Challenger2
Strong scale, closing on the leaders.
Pharming Group N.V.CSL Behring (a CSL Limited company)
Contender2
Focused players with pockets of strength.
KalVista Pharmaceuticals Inc.Sobi (Swedish Orphan Biovitrum AB)
Niche2
Specialists in a single segment or region.
Horizon Therapeutics plcShire (now part of Takeda)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Hereditary Angioedema Therapeutics Market — a $50M beachhead inside a $835M market.
Beachhead (SOM)$50Mobtainable near-term
Serviceable (SAM)$304Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
C1 Esterase Inhibitors
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer76 fit
Kallikrein Inhibitors
Strong fit — clear ROI and a fast path to value.
End user69 fit
Bradykinin B2 Receptor Antagonists
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hereditary Angioedema Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation14%
Closed-won5%
$13.9KCAC
$69KLTV
5.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hereditary Angioedema Therapeutics Market is a durable-growth opportunity — $10.1B by 2033, compounding at 8.0%.
TAM · 2025$5.46Btoday
TAM · 2033$10.1Bforecast
CAGR8.0%2027–2033
Cumulative$68.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.1BTotal addressable market
SAM$3.79BServiceable available market
SOM$753MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.1BLarge & growingTAM by 2033 at 8.0% CAGR
$3.79BServiceable nowreachable with today’s model
$753MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.87BBear5.2% CAGR
$10.1BBase8.0% CAGR
$12.9BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hereditary Angioedema Therapeutics Market — a $780M market by 2033. Plan: grow share from 10.9% to 16.9%.
Market size · 2033$780Mtotal addressable
Market CAGR4.7%2027–2033
Target share16.9%from 10.9% today
Revenue ambition$132Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 16.9% | Ahead |
| Revenue | $80M | $132M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.7% | 41.5% | Behind |
| Customer retention | 90.8% | 96.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Indication capability
A defensible second engine — invest in Treatment Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Indication
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hereditary Angioedema Therapeutics Market conversation — a $554M market you can size, segment and defend in minutes.
Market size · 2033$554Mtotal opportunity
Growth3.4%CAGR to 2033
Addressable buyers1,485+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Takeda Pharmaceutical Company LimitedBioCryst Pharmaceuticals Inc.Pharming Group N.V.CSL Behring (a CSL Limited company)KalVista Pharmaceuticals Inc.Sobi (Swedish Orphan Biovitrum AB)Horizon Therapeutics plcShire (now part of Takeda)+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hereditary Angioedema Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hereditary Angioedema Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Hermetic Centrifuge Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportHermetic CO2 Compressors Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportHermetic Oil (PVE based) Used in Room AC Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportHermetic Plastic Containers Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHermetic Reciprocating Compressor (0-400 watt, LBP condition for Household & Commercial Refrigerator) Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportHermetic Seals Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportHermetic Sliding Door Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportHermetic Turbocompressor Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportHermetic Vapor Compression System Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportHermosetting Polymers Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportHernia Drug Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportHernia Mesh Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.